Bcl-2-EEE Mutant Cell Line for Serum-Free Protein Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for increasing the longevity and productivity of cell cultures in bioreactors for recombinant protein production, such as using apoptosis inhibitors, have yielded unpredictable results, and there is a need for improved host cells that can thrive in serum-free media and produce proteins efficiently without lengthy adaptation periods.
Innovation Solution
The development of an Sp2/0 cell line transfected with a Bcl-2 gene carrying T69E, S70E, and S87E mutations (Bcl-2-EEE), cultivated in step-wise increased methotrexate concentrations, and adapted to grow in serum-free medium, along with the use of caspase inhibitors and HPV-16 oncoproteins E6 and E7, to enhance cell survival and protein production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If apoptosis inhibitors such as Bcl-2 are used to increase cell lifespan, then cell culture longevity is improved, but protein production yield becomes unpredictable and cell density decreases
Solution Approach 1:
The patent applies parameter changes by introducing specific point mutations (T69E, S70E, S87E) in the Bcl-2 gene to alter its functional properties. These mutations modify the protein's interaction with apoptotic substrates, enhancing its anti-apoptotic activity while maintaining compatible cell density and protein production characteristics. This precise molecular modification allows optimization of cell lifespan without the unpredictable effects observed with wild-type Bcl-2 overexpression.
2Productivity
If cell density is increased to improve productivity, then protein production is enhanced, but cell lifespan is reduced
Solution Approach 1:
The mutated Bcl-2-EEE protein acts as an intermediary that decouples the relationship between cell density and lifespan. By specifically inhibiting apoptotic pathways through its mutated structure, Bcl-2-EEE allows cells to maintain high densities without the usual lifespan reduction, effectively mediating between productivity requirements and longevity constraints.
3Productivity
If cells are adapted to serum-free media to reduce costs and time, then production efficiency is improved, but adaptation period is lengthened
Solution Approach 1:
The patent applies preliminary action by pre-adapting the Sp2/0 cell line to serum-free conditions before the actual protein production run. The cells undergo a gradual adaptation process where serum is progressively reduced in the culture medium, allowing the cells to develop the necessary metabolic adjustments and survival mechanisms in advance. This preliminary adaptation eliminates the need for lengthy adaptation periods during production, directly improving productivity while minimizing time loss.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.